Shingo Tamura

832 total citations
38 papers, 578 citations indexed

About

Shingo Tamura is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shingo Tamura has authored 38 papers receiving a total of 578 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 11 papers in Surgery and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shingo Tamura's work include Cancer Immunotherapy and Biomarkers (9 papers), Colorectal Cancer Treatments and Studies (7 papers) and Bladder and Urothelial Cancer Treatments (6 papers). Shingo Tamura is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Colorectal Cancer Treatments and Studies (7 papers) and Bladder and Urothelial Cancer Treatments (6 papers). Shingo Tamura collaborates with scholars based in Japan and United States. Shingo Tamura's co-authors include Hitoshi Kusaba, Eishi Baba, Hiroshi Ariyama, Koichi Akashi, Masashi Nomi, Kohsuke Takeda, Makoto Ikeya, Isao Oishi, Mamoru Ito and Hirohei Yamamura and has published in prestigious journals such as Cancer Research, Oncogene and Scientific Reports.

In The Last Decade

Shingo Tamura

34 papers receiving 574 citations

Peers

Shingo Tamura

ONCOL

PRM

SURGE

IMMUN

Steffen Heeg Germany

Kelly E. Craven United States

So-Young Yeo South Korea

Markus Germann Switzerland

Nina Waldburger Germany

Bingyin Shi China

Masahiko Zuka Japan

Leili Saeednejad Zanjani Iran

Verena Proell Austria

Shailaja Uttamsingh United States

Steffen Heeg Germany

Shingo Tamura

240 ×0.8

ONCOL

273 ×1.0

60 ×0.7

PRM

110 ×1.5

SURGE

38 ×0.6

IMMUN

Citations per year, relative to Shingo Tamura Shingo Tamura (= 1×) peers Steffen Heeg

Countries citing papers authored by Shingo Tamura

Since Specialization

Citations

This map shows the geographic impact of Shingo Tamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shingo Tamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shingo Tamura more than expected).

Fields of papers citing papers by Shingo Tamura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shingo Tamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shingo Tamura. The network helps show where Shingo Tamura may publish in the future.

Co-authorship network of co-authors of Shingo Tamura

This figure shows the co-authorship network connecting the top 25 collaborators of Shingo Tamura. A scholar is included among the top collaborators of Shingo Tamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shingo Tamura. Shingo Tamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Enokida, Tomohiro, Shingo Tamura, Torahiko Nakashima, et al.. (2024). Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma. Frontiers in Oncology. 14. 1379013–1379013.

Minato, Akinori, Takahito Negishi, Naotaka Sakamoto, et al.. (2023). Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study. Anticancer Research. 43(10). 4701–4708. 1 indexed citations

Yamaguchi, Toshihiro, Hirofumi Ohmura, Mamoru Ito, et al.. (2023). Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions. Cancer Immunology Immunotherapy. 72(11). 3543–3558. 5 indexed citations

Minato, Akinori, Takahito Negishi, Naotaka Sakamoto, et al.. (2022). Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab. Cancer Management and Research. Volume 14. 1641–1651. 6 indexed citations

Nishikawa, Kazuo, Shuichi Hironaka, Takashi Inagaki, et al.. (2022). A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site. Japanese Journal of Clinical Oncology. 52(12). 1416–1422. 2 indexed citations

Minato, Akinori, Takahito Negishi, Naotaka Sakamoto, et al.. (2022). The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status. OncoTargets and Therapy. Volume 15. 1321–1330. 1 indexed citations

Minato, Akinori, Takahito Negishi, Naotaka Sakamoto, et al.. (2022). Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study. Clinical Genitourinary Cancer. 20(5). 499.e1–499.e8. 14 indexed citations

Minato, Akinori, Takahito Negishi, Naotaka Sakamoto, et al.. (2021). The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab. Cancer Management and Research. Volume 13. 8049–8056. 17 indexed citations

Negishi, Takahito, Naotaka Sakamoto, Shingo Tamura, et al.. (2021). Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy. In Vivo. 35(5). 2869–2874. 2 indexed citations

10.

Ohmura, Hirofumi, Toshihiro Yamaguchi, Mamoru Ito, et al.. (2020). OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody. British Journal of Cancer. 122(10). 1507–1517. 51 indexed citations

11.

Yamaguchi, Toshihiro, Hitoshi Kusaba, Akitaka Makiyama, et al.. (2018). The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer. Cancer Chemotherapy and Pharmacology. 82(4). 625–633. 12 indexed citations

12.

Kusaba, Hitoshi, Takeharu Yamanaka, Kenta Nio, et al.. (2018). A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy. Medicine. 97(25). e11042–e11042. 2 indexed citations

13.

Ito, Mamoru, Hitoshi Kusaba, Junji Kishimoto, et al.. (2017). Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer. Anti-Cancer Drugs. 28(10). 1166–1173. 3 indexed citations

14.

Shirakawa, Tsuyoshi, Michitaka Nakano, Kenta Nio, et al.. (2016). Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients. Anti-Cancer Drugs. 27(9). 891–898. 2 indexed citations

15.

Nio, Kenta, Shuji Arita, Taichi Isobe, et al.. (2015). Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology. 75(4). 829–835. 14 indexed citations

16.

Tamura, Shingo, Hitoshi Kusaba, Naoki Kubo, et al.. (2014). Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer. Medical Oncology. 31(3). 856–856. 6 indexed citations

17.

Kusaba, Hitoshi, Yuta Okumura, Masato Komoda, et al.. (2014). Efficacy and Safety of an Increased-dose of Dexamethasone in Patients Receiving Fosaprepitant Chemotherapy in Japan. Asian Pacific Journal of Cancer Prevention. 15(1). 461–465. 3 indexed citations

18.

Isobe, Taichi, Keita Uchino, Hiroshi Ariyama, et al.. (2014). Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan.. PubMed. 34(4). 2035–40. 11 indexed citations

19.

Tsuchihashi, Kenji, Keita Uchino, Tsuyoshi Shirakawa, et al.. (2012). Systemic chemotherapy for metastatic non-mucinous appendiceal adenocarcinoma: a case report and literature review. International Cancer Conference Journal. 2(1). 36–40.

20.

Takeuchi, Shigeto, Kohsuke Takeda, Isao Oishi, et al.. (2000). Mouse Ror2 receptor tyrosine kinase is required for the heart development and limb formation. Genes to Cells. 5(1). 71–78. 185 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact